T. Ollila

发表

Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma

J. Butera, D. Treaba, A. Chorzalska, 2021, Blood Advances.

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study

J. Butera, J. Reagan, A. Olszewski, 2022, The oncologist.

Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record.

Ross W Hilliard, J. Reagan, A. Olszewski, 2020, Rhode Island medical journal.

Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study

Mengyang Di, A. Olszewski, T. Ollila, 2019, Leukemia.

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease.

Shaolei Lu, A. Olszewski, Ralph Rogers, 2021, JAMA oncology.

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma

I. Sahin, A. Olszewski, T. Ollila, 2019, OncoTargets and therapy.

Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies

Shaolei Lu, J. Reagan, A. Olszewski, 2022, Cancer.

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence

A. Olszewski, T. Ollila, Thomas A Ollila, 2018, Current Treatment Options in Oncology.

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

L. Gordon, J. Winter, S. Chowdhury, 2022, Blood advances.

Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma

A. Olszewski, T. Ollila, Thomas A Ollila, 2021, Cancer management and research.

Molecular Profiles of Brain and Pulmonary Metastatic Disease in Cancer of Unknown Primary.

D. Dizon, C. Elco, B. Bakow, 2020, The oncologist.

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

R. Advani, Sonali M. Smith, J. Chavez, 2020 .

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers

Sonali M. Smith, P. Venugopal, S. Singer, 2023, American journal of hematology.

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Sonali M. Smith, P. Venugopal, S. Singer, 2023, Leukemia & lymphoma.

Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base

J. Reagan, A. Olszewski, T. Ollila, 2019, Leukemia & lymphoma.

Analysis of Hematology and Oncology Fellowship Website Content and Diversity Representation

Chapman Wei, D. Dizon, M. Quesenberry, 2022, JCO oncology practice.

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma.

D. Treaba, P. Dubielecka, Habibe Kurt, 2020, Blood.

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.

R. Advani, Sonali M. Smith, J. Chavez, 2021, Blood.

Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomas

J. Reagan, A. Olszewski, T. Ollila, 2018, British journal of haematology.

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma

I. Sahin, A. Olszewski, T. Ollila, 2019, OncoTargets and therapy.

Embolization of Inferior Vena Cava Filter Tyne and Right Ventricular Perforation: A Cardiac Missile.

A. Poppas, G. McKendall, A. Ehsan, 2016, The Annals of thoracic surgery.

Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

P. Dubielecka, R. Bannerji, A. Olszewski, 2022, Blood.

Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis

A. Olszewski, Rashida Taher, T. Ollila, 2023, Blood advances.

Radiation therapy in primary testicular lymphoma: does practice match the standard of care?

A. Olszewski, T. Ollila, Thomas A Ollila, 2018, Leukemia & lymphoma.

Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma

A. Olszewski, T. Ollila, Ari Pelcovits, 2023, Cancer management and research.

Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma

A. Olszewski, T. Ollila, 2021 .

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma

I. Sahin, A. Olszewski, T. Ollila, 2019, OncoTargets and therapy.

Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day‐14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease

J. Butera, P. Quesenberry, M. Quesenberry, 2018, Clinical lymphoma, myeloma & leukemia.

Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

T. Ollila, Ari Pelcovits, Charles J. Milrod, 2024, Frontiers in oncology.

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

S. Chowdhury, R. Karmali, P. Torka, 2024, Blood advances.

Drug‐induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia

B. Gallo Marin, E. Firoz, T. Ollila, 2022, American journal of hematology.